AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 5 mg
Number of subjects: 66
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 10 mg
Number of subjects: 66
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg
Number of subjects: 66
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 75 mg
Number of subjects: 66
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 150 mg
Number of subjects: 66
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (all doses)
Number of subjects: 66
Study 7965263 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (150 mg)
Number of subjects: 66
Study 7965263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 3111914 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (125 mg daily for 6 mo)
Number of subjects: 22
Study 3111914 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study 31598837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclinical studies with translational robustness
Number of subjects: 0
Study 31598837 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger studies/programs to maintain statistical power
Number of subjects: 0
Study 31598837 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of bias in translational studies
Number of subjects: 0
Study 31270665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tor Vergata Stroke Score (TVSS)
Number of subjects: 270
Study 27518491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 16
Study 27518491 — intervention group
Group type: COMPARATOR
Intervention: Fibromyalgia Education (control)
Number of subjects: 16
Study 26136485 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone hexacetonide (TH) 40 mg IA injection
Number of subjects: 100
Study 26136485 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone acetate (MA) 40 mg IA injection
Number of subjects: 100
Study 22732768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium
Number of subjects: 10
Study 22732768 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 10
Study 21149651 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 125
Study 21149651 — intervention group
Group type: COMPARATOR
Intervention: Educational materials (Control)
Number of subjects: 125
Study 21149651 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CES-D scores
Number of subjects: 125
Study 18082489 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow cells (mBMC)
Number of subjects: 100
Study 16940835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose) plus iron supplements
Number of subjects: 1042
Study 16940835 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus iron supplements
Number of subjects: 1042
Study 12898818 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy as a completion of traditional treatment for vocal nodules
Number of subjects: 0
Study 9952383 — intervention group
Group type: EXPERIMENTAL
Intervention: HBY 097 monotherapy (250 mg three times daily)
Number of subjects: 0
Study 9952383 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine plus HBY 097 (750 mg three times daily)
Number of subjects: 0
Study 9952383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with high‐dose HBY 097
Number of subjects: 0
Study 7674680 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory tests with background distractor during intoxication
Number of subjects: 40
Study 7674680 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory tests without background distractor during intoxication
Number of subjects: 40
Study 7674680 — intervention group
Group type: COMPARATOR
Intervention: Memory tests with background distractor while sober
Number of subjects: 40
Study 7674680 — intervention group
Group type: COMPARATOR
Intervention: Memory tests without background distractor while sober
Number of subjects: 40
Study 1970427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (75 to 250 mg/day, mean 170.8)
Number of subjects: 6
Study 1970427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6993250 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 29
Study 6993250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 29
Study 6993250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol and hydralazine
Number of subjects: 29
Study 6993250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6993250 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (during placebo period)
Number of subjects: 29
Study 31993819 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (1 mg/kg bolus and 1 mg/kg/h infusion)
Number of subjects: 56
Study 31993819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31993819 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram and Placebo
Number of subjects: 56
Study 29800299 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidewire catheter (Accucath 18-gauge)
Number of subjects: 93
Study 29800299 — intervention group
Group type: COMPARATOR
Intervention: Standard 18-gauge peripheral intravenous catheter
Number of subjects: 93
Study 24612629 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Psychological Intervention (IPI), including cognitive behaviour therapy for 12 months
Number of subjects: 128
Study 24612629 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counselling (SC) for 12 months
Number of subjects: 128
Study 25381560 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFi therapy etanercept (ETN) combined with methotrexate (MTX)
Number of subjects: 120
Study 25381560 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with MTX with or without additional synthetic disease modifying anti-rheumatic drugs
Number of subjects: 120
Study 23006447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 every 21 days) plus best supportive care (BSC)
Number of subjects: 55
Study 23006447 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 55
Study 23006447 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 every 21 days) plus BSC
Number of subjects: 55
Study 21090832 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 or 80 mg/day plus amlodipine 5 or 10 mg/day
Number of subjects: 1461
Study 21090832 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-pill telmisartan/amlodipine
Number of subjects: 1461
Study 21090832 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/amlodipine
Number of subjects: 1461
Study 21090832 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan or amlodipine monotherapy
Number of subjects: 1461
Study 17642037 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling on medical rehabilitation (Intervention Group - IG)
Number of subjects: 0
Study 17642037 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group - CG)
Number of subjects: 0
Study 16166930 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 500 mg per os 1 hour prior to the procedure
Number of subjects: 0
Study 16166930 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 0
Study 12013195 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 10%
Number of subjects: 24
Study 12013195 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1%
Number of subjects: 24
Study 12013195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepyramine 5%
Number of subjects: 24
Study 12013195 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 24
Study 10413273 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose platelet component (HDP)
Number of subjects: 46
Study 10413273 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose platelet component (LDP)
Number of subjects: 46
Study 7496234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet S (21% energy from saturated fat)
Number of subjects: 67
Study 7496234 — intervention group
Group type: COMPARATOR
Intervention: Diet P (10% energy from saturated fat)
Number of subjects: 67
Study 7496234 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet S and P
Number of subjects: 67
Study 2197381 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate 100 mg plus codeine 60 mg
Number of subjects: 200
Study 2197381 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate 50 mg plus codeine 30 mg
Number of subjects: 200
Study 2197381 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate 100 mg
Number of subjects: 200
Study 2197381 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 200
Study 2197381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 6992844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied three times daily
Number of subjects: 95
Study 6992844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide cream applied once daily
Number of subjects: 95
Study 6992844 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone
Number of subjects: 95
Study 31605735 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated palliative home care (PHC) with an average of 3.4 visits, focusing on disease insight, symptom management, and care planning.
Number of subjects: 39
Study 31605735 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated palliative home care (PHC)
Number of subjects: 39
Study 31605735 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 39
Study 31154809 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 61
Study 31154809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 28244718 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa L. (HS) tea for 30 days
Number of subjects: 48
Study 28244718 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum Makino (GP) tea for 30 days
Number of subjects: 48
Study 27007076 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 62
Study 27007076 — intervention group
Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 62
Study 24676694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.035 mg ethinyl estradiol + 2 mg cyproterone acetate (group A)
Number of subjects: 52
Study 24676694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg ethinyl estradiol + 3 mg drospirenone (group B)
Number of subjects: 52
Study 23141085 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR > 0.75 group
Number of subjects: 106
Study 23141085 — intervention group
Group type: COMPARATOR
Intervention: FFR ≤ 0.75 group
Number of subjects: 106
Study 23141085 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD ≥ 1.6 mm
Number of subjects: 106
Study 19071184 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM1000
Number of subjects: 90
Study 19071184 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2000
Number of subjects: 90
Study 19071184 — intervention group
Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 90
Study 17938746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam treatment
Number of subjects: 507
Study 17938746 — intervention group
Group type: COMPARATOR
Intervention: Resin composite treatment
Number of subjects: 507
Study 15866414 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US)
Number of subjects: 12
Study 15866414 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound (US)
Number of subjects: 12
Study 12123116 — intervention group
Group type: EXPERIMENTAL
Intervention: New glass ionomer filling material (Chem‐Flex)
Number of subjects: 41
Study 12123116 — intervention group
Group type: COMPARATOR
Intervention: Control material fillings
Number of subjects: 41
Study 10225582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (400 mg, every 8 h)
Number of subjects: 540
Study 10225582 — intervention group
Group type: COMPARATOR
Intervention: Intravenous standard therapy (beta-lactam)
Number of subjects: 540
Study 10225582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ciprofloxacin (400 mg, every 8 h) plus beta-lactam
Number of subjects: 540
Study 10225582 — intervention group
Group type: COMPARATOR
Intervention: Intravenous standard therapy (aminoglycoside plus beta-lactam)
Number of subjects: 540
Study 10225582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg, every 12 h)
Number of subjects: 540
Study 10225582 — intervention group
Group type: COMPARATOR
Intervention: Standard oral therapy
Number of subjects: 540
Study 1639052 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 IU of retinyl palmitate)
Number of subjects: 83
Study 1639052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 6376479 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 184
Study 6376479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin
Number of subjects: 184
Study 6376479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 30499929 — intervention group
Group type: EXPERIMENTAL
Intervention: In the Classroom Web site (treatment group)
Number of subjects: 100
Study 30499929 — intervention group
Group type: COMPARATOR
Intervention: LEARNet Web site (control group)
Number of subjects: 100
Study 28847146 — intervention group
Group type: EXPERIMENTAL
Intervention: On-X mechanical valve
Number of subjects: 360
Study 28847146 — intervention group
Group type: COMPARATOR
Intervention: St Jude mechanical valve
Number of subjects: 360
Study 28847146 — intervention group
Group type: EXPERIMENTAL
Intervention: On-X mechanical valve (25 mm size)
Number of subjects: 360
Study 28847146 — intervention group
Group type: COMPARATOR
Intervention: St Jude mechanical valve (25 mm size)
Number of subjects: 360
Study 27266282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 7453
Study 27266282 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 7453
Study 25751673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic intravenous fluids (sodium chloride, 0.9%, and dextrose, 5%)
Number of subjects: 110
Study 25751673 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic intravenous fluids (sodium chloride, 0.45%, and dextrose, 5%)
Number of subjects: 110
Study 25751673 — intervention group
Group type: COMPARATOR
Intervention: Hypotonic intravenous fluids
Number of subjects: 110
Study 25751673 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic intravenous fluids
Number of subjects: 110
Study 24331798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban (10 µg/kg bolus within 3 min followed by 0.10‐0.15 µg×kg(‐1)×min(‐1) for 36 h i.v.)
Number of subjects: 246
Study 24331798 — intervention group
Group type: COMPARATOR
Intervention: Control (saline i.v. for 36 h)
Number of subjects: 246
Study 24331798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 246
Study 24331798 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 246
Study 20347467 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous smoking
Number of subjects: 78
Study 20347467 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence with transdermal nicotine patch (TNP)
Number of subjects: 78
Study 20347467 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence with placebo patch
Number of subjects: 78
Study 20347467 — intervention group
Group type: COMPARATOR
Intervention: Never smokers (control)
Number of subjects: 78
Study 20347467 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (vitamin C levels)
Number of subjects: 78
Study 20347467 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers (PINP levels)
Number of subjects: 78
Study 20347467 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 78
Study 18554238 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg entecavir
Number of subjects: 84
Study 18554238 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg entecavir
Number of subjects: 84
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 233
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 233
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 233
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 233
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 233
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 233
Study 21794296 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall NSAID therapy
Number of subjects: 233
Study 14670418 — intervention group
Group type: COMPARATOR
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 108
Study 14670418 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted subepithelial keratectomy (LASEK)
Number of subjects: 108
Study 14670418 — intervention group
Group type: COMPARATOR
Intervention: PRK
Number of subjects: 108
Study 14670418 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 108
Study 10971602 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) 25 microg/kg daily
Number of subjects: 10
Study 10971602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10971602 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF)
Number of subjects: 10
Study 9256564 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week school-based child- and parent-focused psychosocial intervention
Number of subjects: 128
Study 9256564 — intervention group
Group type: COMPARATOR
Intervention: Monitoring group
Number of subjects: 128
Study 8285335 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane-fentanyl anaesthesia with nitrous oxide in oxygen
Number of subjects: 42
Study 8285335 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-fentanyl anaesthesia with air in oxygen
Number of subjects: 42
Study 8285335 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol-fentanyl anaesthesia with nitrous oxide in oxygen
Number of subjects: 42
Study 8285335 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 l.min‐1 of oxygen by nasal catheter
Number of subjects: 42
Study 8285335 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative days 1, 2 and 3
Number of subjects: 42
Study 3104180 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches delivering 10 mg/24 hours
Number of subjects: 10
Study 31982957 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM patients
Number of subjects: 28
Study 31982957 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM patients with mild/moderate clinical status
Number of subjects: 28
Study 31982957 — intervention group
Group type: EXPERIMENTAL
Intervention: DCM patients with severe clinical status
Number of subjects: 28
Study 31982957 — intervention group
Group type: COMPARATOR
Intervention: Controls (TAAA)
Number of subjects: 28
Study 29187046 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 49
Study 29187046 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 26626365 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with bovine milk-derived oligosaccharides and Bifidobacterium animalis subsp. lactis (B. lactis) strain CNCM I-3446
Number of subjects: 0
Study 26626365 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented control formula
Number of subjects: 0
Study 26626365 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (reference group)
Number of subjects: 0
Study 26626365 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formula (BMOS + B. lactis)
Number of subjects: 0
Study 24786196 — intervention group
Group type: EXPERIMENTAL
Intervention: Jitai tablet treatment
Number of subjects: 99
Study 24786196 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 99
Study 24786196 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels in heroin addicts
Number of subjects: 99
Study 24786196 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 99
Study 22989359 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised FSH regime (150 IU/day, 225-450 IU/day, and 100 IU/day)
Number of subjects: 100
Study 22989359 — intervention group
Group type: COMPARATOR
Intervention: Standard FSH regime
Number of subjects: 100
Study 22989359 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised FSH regime
Number of subjects: 100
Study 20466951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental practitioner advice and brief counseling intervention including nicotine replacement therapy
Number of subjects: 2549
Study 20466951 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2549
Study 18085424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline HCL (20%) sclerotherapy after aspiration
Number of subjects: 70
Study 18085424 — intervention group
Group type: COMPARATOR
Intervention: Control group (aspiration without sclerotherapy)
Number of subjects: 70
Study 15819670 — intervention group
Group type: EXPERIMENTAL
Intervention: DELFIA analysis in vCJD patients
Number of subjects: 4
Study 15819670 — intervention group
Group type: EXPERIMENTAL
Intervention: DELFIA analysis in non-CJD neurological patients
Number of subjects: 4
Study 15819670 — intervention group
Group type: EXPERIMENTAL
Intervention: DELFIA analysis in sCJD patients
Number of subjects: 4
Study 15819670 — intervention group
Group type: COMPARATOR
Intervention: Flow cytometry in neurological controls
Number of subjects: 4
Study 15819670 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry in all groups
Number of subjects: 4